Xuena Wang

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

David J. Kuter, Mathias Rummel, Ralph V. Boccia et al. · New England Journal of Medicine · 2010 · 417 citations · Full text

Detection of cancer-specific markers amid massive mass spectral data

Wei Zhu, Xuena Wang, Yeming Ma et al. · Proceedings of the National Academy of Sciences · 2003 · 182 citations · Full text

Pathology, Gynecology, Tumor Biology +16

Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

Francesco Rodeghiero, Roberto Stasi, Aristoteles Giagounidis et al. · European Journal Of Haematology · 2013 · 110 citations

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

Douglas B. Cines, Terry Gernsheimer, Jeffrey S. Wasser et al. · International Journal of Hematology · 2015 · 94 citations · Full text

Thrombopoiesis, Thrombosis, Venous Thrombosis +13

Health‐related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care

David J. Kuter, Susan D. Mathias, Mathias Rummel et al. · American Journal of Hematology · 2012 · 77 citations

Quality Of Life, Immunology, Pharmacotherapy +17